Cullinan Therapeutics Announces Oversubscribed $280 million Private Placement
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/2/2026
- Wall St ends higher as stocks reclaim some shine
- Broadcom raises AI chip forecast as Big Tech keeps writing bigger checks
- Snowflake soars 20% on earnings beat and raised guidance
- Oil settles 1% higher, as US-Iran strikes threaten supplies
- Could Apple’s foldable iPhone be a $14B opportunity? Morgan Stanley weighs in
Cullinan Oncology Inc. (CGEM) PT Raised to $30 at BTIG
April 17, 2024 5:08 AM EDTBTIG analyst Kaveri Pohlman raised the price target on Cullinan Oncology Inc. (NASDAQ: CGEM) to $30.00 (from $20.00) while maintaining a Buy rating.
The analyst comments "We are increasing our PT to $30 from $20 after Cullinan's recent corporate update since CLN-978's drug... More
